Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dr. Reddy's Laboratories Ltd Common Stock (NY:RDY)

13.35 +0.08 (+0.57%)
Streaming Delayed Price Updated: 11:34 AM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dr. Reddy's Laboratories Ltd Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy's Laboratories-ADR (NYSE:RDY) Passes Peter Lynch's GARP Investment Filter ↗
Via Chartmill
News headline image
Dr. Reddy's Laboratories (NYSE:RDY) Passes Key Peter Lynch GARP Screens ↗
Dr. Reddy's Laboratories exemplifies Peter Lynch's GARP strategy with strong earnings growth, a low PEG ratio, and a debt-free balance sheet. 
Via Chartmill
News headline image
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies
From Aurigene Oncology Limited
Via Business Wire
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Fits the Peter Lynch Investment Strategy ↗
Dr. Reddy's Labs fits the Peter Lynch investment model with strong EPS growth, a low PEG ratio, minimal debt, and high ROE, making it a compelling GARP stock. 
Via Chartmill
News headline image
Dr. Reddy's Laboratories (NYSE:RDY) Fits the Peter Lynch Investment Strategy ↗
Dr. Reddy's Laboratories aligns with Peter Lynch's GARP strategy, showing strong financial health, steady earnings growth, and an attractive valuation with a low PEG ratio. 
Via Chartmill
News headline image
Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025
From Aurigene Oncology Limited
Via Business Wire
News headline image
Dr. Reddy's Laboratories-ADR (NYSE:RDY) Meets Key Peter Lynch Investment Criteria ↗
Discover Dr. Reddy's (RDY), a Peter Lynch-style GARP stock with strong earnings growth, low debt, and an attractive PEG ratio for long-term value. 
Via Chartmill
News headline image
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs ↗
The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply concerns. 
Via Benzinga
Topics Government World Trade
News headline image
Dr. Reddy's Laboratories-ADR (NYSE:RDY) Fits the Peter Lynch GARP Strategy ↗
Dr. Reddy's Laboratories (RDY) exemplifies Peter Lynch's GARP strategy with strong 23.6% EPS growth, a low 0.80 PEG ratio, and excellent financial health. 
Via Chartmill
News headline image
Dr. Reddy's Laboratories (NYSE:RDY): A Peter Lynch-Style GARP Investment ↗
Discover how Dr. Reddy's Laboratories (RDY) exemplifies Peter Lynch's GARP investing strategy with strong earnings growth, a low PEG ratio, and a robust financial profile. 
Via Chartmill
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Fits Peter Lynch's Growth at a Reasonable Price (GARP) Strategy ↗
Dr. Reddy's Labs (RDY) fits Peter Lynch's GARP strategy with steady earnings growth, strong profitability, low debt, and fair valuation—ideal for long-term investors. 
Via Chartmill
News headline image
Dr. Reddy’s Reports Record Revenues in Q1, Signals Steady Execution Through Transition Year
Via AB Newswire
Topics Earnings
News headline image
Dr. Reddy’s Q1FY26 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) – A GARP Candidate Worth Watching ↗
DR. REDDY'S LABORATORIES (NYSE:RDY) fits the GARP model with strong earnings growth, solid profitability, and a reasonable valuation, making it a candidate for long-term investors. 
Via Chartmill
Expanding the Preventive Care Frontier: Dr. Reddy’s Launches Sanofi’s Beyfortus® in India
Via AB Newswire
Topics Death
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - A GARP Candidate in Pharmaceuticals ↗
DR. REDDY'S LABORATORIES (NYSE:RDY) offers strong historical growth, reasonable valuation, and solid financial health, making it a candidate for GARP investors. 
Via Chartmill
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - A GARP Candidate Worth Considering ↗
DR. REDDY'S LABORATORIES (NYSE:RDY) fits the GARP mold with strong historical growth, a low PEG ratio, and robust financials, making it a candidate for long-term investors. 
Via Chartmill
News headline image
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug ↗
Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives. 
Via Benzinga
News headline image
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
From Alvotech
Via GlobeNewswire
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - A GARP Candidate Worth Considering ↗
DR. REDDY'S LABORATORIES (NYSE:RDY) offers strong earnings growth, low debt, and solid profitability, making it a candidate for GARP investors. Read why it fits the Peter Lynch strategy. 
Via Chartmill
News headline image
Dr. Reddy’s Q4 & Full Year FY25 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
How does DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) stack up against Peter Lynch’s investment principles? ↗
Peter Lynch’s approach focused on identifying undervalued growth stocks with simple, scalable businesses. We examine whether DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) fits the characteristics of a... 
Via Chartmill
News headline image
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline ↗
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs. 
Via Benzinga
Topics Government Supply Chain World Trade
News headline image
Would Peter Lynch consider DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) a winning stock? ↗
Let’s dive into DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) using Peter Lynch’s key investing principles, from earnings growth and debt levels to long-term scalability and valuation. 
Via Chartmill
News headline image
Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
From Alvotech
Via GlobeNewswire
News headline image
Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.